CDT Stock Forecast 2025-2026
Distance to CDT Price Targets
CDT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Conduit Pharmaceuticals (CDT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CDT and similar high-potential opportunities.
Latest CDT Stock Price Targets & Analyst Predictions
CDT has shown a year-to-date change of -91.0% and a 1-year change of -99.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CDT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDT Analyst Ratings
CDT Price Target Range
Latest CDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Conduit Pharmaceuticals Inc. (CDT) Competitors
The following stocks are similar to Conduit Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Conduit Pharmaceuticals Inc. (CDT) Financial Data
Conduit Pharmaceuticals Inc. has a market capitalization of $5.92M with a P/E ratio of 421.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +262.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Conduit Pharmaceuticals Inc. (CDT) Business Model
About Conduit Pharmaceuticals Inc.
Develops therapeutic treatments for chronic diseases.
Conduit Pharmaceuticals operates within the biotechnology sector, focusing on advancing clinical phase drug candidates that target chronic diseases with unmet medical needs. The company generates revenue by developing and potentially commercializing innovative therapies, leveraging collaborations with research institutions and healthcare entities to enhance its research and development efforts.
The company emphasizes a robust pipeline in areas such as autoimmune disorders and oncology, aiming to deliver breakthrough therapies that can significantly improve patient outcomes. With a commitment to scientific excellence and innovation, Conduit Pharmaceuticals is positioned to make a substantial impact on the pharmaceutical market and healthcare delivery.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Dr. David Joszef Tapolczay
Country
United States
IPO Year
2023
Website
www.conduitpharma.comConduit Pharmaceuticals Inc. (CDT) Latest News & Analysis
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced leadership changes aimed at supporting the company's growth and execution strategy as of April 16, 2025.
Leadership changes often signal strategic shifts, impacting company performance and investor confidence. Positive adjustments can enhance growth prospects, influencing stock value.
Conduit Pharmaceuticals has filed a new cocrystal patent for VTAMA® (tapinarof), aiming for high-value licensing partnerships as the drug nears its 2027 exclusivity expiration.
Conduit Pharmaceuticals' patent filing for VTAMA® could enhance its market position ahead of exclusivity expiration, attracting lucrative licensing deals and boosting investor confidence.
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
19 days agoConduit has obtained a composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator for autoimmune disorders, enabling clinical development and potential partnerships.
Conduit's patent for AZD1656 enhances its competitive edge in autoimmune disorders, paving the way for potential partnerships and increased market value.
Conduit Pharmaceuticals is advancing its pipeline with preclinical lupus studies for AZD5658, Phase IIa trial plans for AZD1656, and IP expansion, indicating potential near-term growth.
Conduit Pharmaceuticals' advancements in lupus studies and trial designs enhance its growth potential, signaling possible value increases and upcoming milestones that could attract investor interest.
Conduit Pharmaceuticals Inc. has requested an extension from Nasdaq to comply with listing rules regarding minimum bid price and market value as of February 11, 2025.
Conduit Pharmaceuticals' request for an extension to comply with Nasdaq listing rules signals potential financial instability, affecting investor confidence and stock performance.
Conduit Pharmaceuticals (Nasdaq: CDT) has completed initial milestones in Phase II of its collaboration with Sarborg Limited to enhance drug development using AI and cybernetics.
Conduit's collaboration with Sarborg enhances its drug development efficiency through AI, potentially leading to cost savings and faster product launches, impacting future revenue and stock performance.
Frequently Asked Questions About CDT Stock
What is Conduit Pharmaceuticals Inc.'s (CDT) stock forecast for 2025?
Analyst forecasts for Conduit Pharmaceuticals Inc. (CDT) are not currently available. The stock is trading at $0.62.
Is CDT stock a good investment in 2025?
Analyst ratings for CDT are not currently available. The stock is currently trading at $0.62. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDT stock?
Price predictions from Wall Street analysts for CDT are not currently available. The stock is trading at $0.62.
What is Conduit Pharmaceuticals Inc.'s business model?
Conduit Pharmaceuticals operates within the biotechnology sector, focusing on advancing clinical phase drug candidates that target chronic diseases with unmet medical needs. The company generates revenue by developing and potentially commercializing innovative therapies, leveraging collaborations with research institutions and healthcare entities to enhance its research and development efforts.
What is the highest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $0.62.
What is the lowest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $0.62.
What is the overall CDT consensus from analysts for Conduit Pharmaceuticals Inc.?
Analyst ratings for CDT are not currently available. The stock is trading at $0.62.
How accurate are CDT stock price projections?
Stock price projections, including those for Conduit Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.